Recent Updates
Recently added Catalysts
HAO Negative Sentiment Score: 35/100

HAOXI HEALTH TECHNOLOGY LIMITED INDEX TO CONSOLIDATED FINANCIAL STATEMENTS CONTENTS PAGE(S) CONSOLIDATED FINANCIAL STATEMENTS CONDENSED UNAUDITED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND JUNE 30, 2024 F-2

Key Takeaway: Haoxi Health Technology Limited released its consolidated financial statements for the six months ending December 31, 2024, reporting a notable decline in financial performance. The company experienced a net loss of $232,533, a stark contrast to the net income of $760,198 recorded in the same period the previous year. Additionally, gross profit fell significantly from $1,201,388 to $480,393. The cash flow from operating activities also indicated financial strain, with a net cash outflow of $2,250,334 compared to an inflow of $301,000 in the prior year.

Market Sentiment Analysis

CONCERNS & RISKS

  • Haoxi Health Technology Limited reported a net loss of $232,533 for the six months ending December 31, 2024, contrasting with a net income of $760,198 in the same period of 2023.
  • The company's gross profit sharply decreased to $480,393 from $1,201,388 year-over-year.
  • Cash provided by operating activities showed a significant net outflow of $2,250,334, as opposed to a cash inflow of $301,000 for the previous year.

Full Press Release Details

HAOXI HEALTH TECHNOLOGY LIMITED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
CONTENTS PAGE(S)
CONSOLIDATED FINANCIAL STATEMENTS
CONDENSED UNAUDITED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND JUNE 30, 2024 F-2
CONDENSED UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) FOR THE SIX MONTHS ENDED DECEMBER 31, 2024 AND 2023 F-3
CONDENSED UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED DECEMBER 31, 2024 AND 2023 F-4
CONSOLIDATEDUNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE FISCAL YEARS ENDED DECEMBER 31, 2024 AND JUNE 30, 2024 F-5
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS F-6 - F-24
HAOXI HEALTH TECHNOLOGY LIMITED
UNAUDITED CONSOLIDATED BALANCE SHEETS
December 31, 2024 June 30, 2024
(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents $ 9,096,424 $ 6,655,734
Trade receivable, net 734,344 226,747
Supplier advances 5,671,682 5,174,302
Other receivables, net 219,495 235,382
Loan to third parties 4,098,405 3,087,665
Total current assets 19,820,350 15,379,830
Non-current assets
Property and equipment, net 116,193 126,743
Intangible assets, net 2,010,667 -
Operating right-of-use asset 119,562 -
Total non-current assets 2,246,422 126,743
Total Assets $ 22,066,772 $ 15,506,573
LIABILITIES AND EQUITY
Current Liabilities
Short-term loans $ 1,121,668 $ 833,521
Accounts payable 674,563 653,694
Due to related parties 6,187 6,187
Advance from customers 724,551 1,185,130
Taxes payable 541,499 1,044,532
Accrued expenses and other liabilities 83,524 102,436
Salary and welfare payable 42,243 41,075
Operating right-of-use liabilities-current 78,580 -
Long-term accounts payable-current 20,615 -
Total current liabilities 3,293,430 3,866,575
Non-current Liabilities
Operating right-of-use liabilities-non-current -
Long-term accounts payable 30,619 66,365
Long-term borrowing - 301,678
Total non-current liabilities 30,619 368,043
Total Liabilities 3,324,049 4,234,618
Commitments and contingencies
SHAREHOLDERS'EQUITY:
Class A Ordinary Shares (Par value US$ 0.0025 per share, 6,000,000 shares authorized 2,205,600 , and 598,800 shares issued and outstanding as of December 31,2024 and June 30,2024,respectively) 5,514 1,497
Class B Ordinary Shares (Par value US$ 0.0025 per share, 2,000,000 shares authorized, and 690,800 and 690,800 shares issued and outstanding as at December 31, 2024 and June 30, 2024, respectively) 1,727 1,727
Additional paid-in capital 18,335,820 10,589,916
Retained earnings 490,674 723,207
Accumulated other comprehensive loss ( 91,012 ) ( 44,392 )
Total shareholders' equity 18,742,723 11,271,955
Total liabilities and shareholders' equity $ 22,066,772 $ 15,506,573
The accompanying notes are an integral part of
these condensed unaudited consolidated financial statements.
HAOXI HEALTH TECHNOLOGY LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS)
Six Months Ended December 31,
2024 2023
(Unaudited) (Unaudited)
Revenues $ 23,954,998 $ 23,503,910
Cost of revenues ( 23,474,605 ) ( 22,302,522 )
Gross profit 480,393 1,201,388
Operating expenses:
Selling 30,273 20,564
General and administrative 509,915 331,610
Research and development 67,556 30,842
Total operating expenses 607,744 383,016
(Loss) income from operations ( 127,351 ) 818,372
Other income (loss):
Financial income 133,652 -
Financial expense - ( 16,789 )
Other expense ( 4,224 ) ( 1,355 )
Total other income (loss), net 129,428 ( 18,144 )
Income before income taxes 2,077 800,228
Income tax expense ( 234,610 ) ( 40,030 )
Net (loss) income $ ( 232,533 ) $ 760,198
Comprehensive income
Foreign currency translation loss ( 46,620 ) ( 604,934 )
Total Comprehensive loss (income) $ ( 279,153 ) $ 155,264
Earnings per ordinary share*
- Basic and diluted $ ( 0.13 ) $ 0.64
Weighted average number of ordinary shares outstanding
-Basic and diluted 1,814,800 1,179,200
Retrospectively restated for effect of reverse share split on January 10, 2025 (see Note 12 and Note 16).
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
HAOXI HEALTH TECHNOLOGY LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
Six Months Ended December 31,
2024 2023
(Unaudited) (Unaudited)
Cash flows from operating activities
Net income (loss) $ ( 232,533 ) $ 760,198
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of property and equipment 9,531 11,584
Changes in operating assets and liabilities:
Trade receivable ( 513,188 ) ( 208,353 )
Supplier advances ( 545,599 ) ( 1,001,155 )
Other receivables, net 13,969 ( 544,298 )
Accounts payable 26,660 963,687
Advance from customers ( 453,648 ) ( 488,561 )
Accrued expenses and other liabilities ( 18,163 ) 165,356
Taxes payable ( 497,619 ) 640,938
Operating lease right-of-use assets ( 120,418 ) 44,661
Operating lease liabilities 79,143 ( 44,661 )
Salary and welfare payable 1,531 1,604
Net cash provided by (used in) operating activities ( 2,250,334 ) 301,000
Cash flows from investing activities
Purchase of property and equipment ( 5,135 ) ( 16,162 )
Purchase of intangible assets ( 2,025,063 ) -
Loan to third parties ( 1,044,625 ) -
Net cash used in investing activities ( 3,074,823 ) ( 16,162 )
Cash flows from financing activities
Proceeds from short-term borrowings 891,514 300,335
Repayment of short-term borrowings ( 895,344 ) ( 101,974 )
Due from a shareholder 53 60,299
Deferred listing costs - ( 19,264 )
Net procees from the follow-on offering 7,749,921 -
Net cash Provided by financing activities 7,746,144 239,396
Effect of foreign exchange rate on cash and restricted cash 19,703 ( 614,803 )
Net increase (decrease) in cash 2,440,690 ( 90,569 )
Cash at the beginning of the period 6,655,734 1,203,203
Cash at the end of the period $ 9,096,424 $ 1,112,634
Supplemental disclosures of cash flow information:
Income taxes paid $ 5,257 $ 19,682
Interest paid $ 22,490 $ 15,181
Operating right-of-use asset 119,562 46,213
The accompanying notes are an integral part of
these consolidated financial statements.
HAOXI HEALTH TECHNOLOGY LIMITED
UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES
IN ACCUMULATED EQUITY
Ordinary shares* Additional paid-in Accumulated Accumulated other comprehensive Total shareholders'
Shares Amount capital deficit income (loss) equity
Balance as of June 30, 2023 1,179,200 $ 2,948 $ 2,176,796 $ ( 568,460 ) $ ( 54,740 ) $ 1,566,505
Net Income 760,198 760,198
Foreign currency translation gain ( 604,934 ) ( 604,934 )
Balance as of December 31, 2023 1,179,200 $ 2,948 $ 2,176,796 $ 191,738 $ ( 659,674 ) $ 1,721,808
Net income - - - 531,469 - 531,469
Issuance of ordinary shares 110,400 276 8,413,120 8,413,396
Foreign currency translation adjustment - - - - 615,282 615,282
Balance as of June 30, 2024 1,289,600 $ 3,224 $ 10,589,916 $ 723,207 $ ( 44,392 ) $ 11,271,955
Net income - - - ( 232,533 ) ( 232,533 )
Issuance of ordinary shares 1,606,800 4,017 7,745,903 - - 7,749,921
Foreign currency translation adjustment - - - - ( 46,620 ) ( 46,620 )
Balance as of December 31, 2024 2,896,400 $ 7,241 $ 18,335,819 $ 490,674 $ ( 91,012 ) $ 18,742,723
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - ORGANIZATION AND BUSINESS DESCRIPTION
Haoxi Health Technology Limited ("Haoxi")
is a company incorporated under the laws of the Cayman on August 5, 2022. It is a holding company with no business operation.
On August 30, 2022, Haoxi formed its wholly owned
subsidiary, Haoxi Information Limited ("Haoxi HK"), in Hong Kong. On October 13, 2022, Haoxi HK formed its wholly owned subsidiary,
Beijing Haoxi Health Technology Co., Limited ("WFOE"), in the People's Republic of China (the "PRC").
Beijing Haoxi Digital Technology Co., Ltd. ("Haoxi
BJ") is a limited liability company incorporated on September 26, 2018, under the laws of China.
On November 25, 2022, WFOE acquired 100% equity
interest of Haoxi BJ, as a result, Haoxi BJ became a wholly-owned subsidiary of WFOE.
As described below, Haoxi, through a restructuring
which is accounted for as a reorganization of entities under common control (the "Reorganization"), became the ultimate parent
entity of its subsidiary, Haoxi BJ. Accordingly, Haoxi consolidates Haoxi BJ's operations, assets, and liabilities. Haoxi and its
subsidiaries, are collectively hereinafter referred as the "Company."
Haoxi together with its wholly owned subsidiaries,
Haoxi HK, WFOE, and Haoxi BJ, were effectively controlled by the same shareholders before and after the Reorganization and, therefore,
the Reorganization is considered one for entities under common control. The consolidation of the Company has been accounted for at historical
cost and prepared on the basis as if the Reorganization had become effective as of the beginning of the first period presented in the
consolidated financial statements.
The Company's current corporate structure is as follows:
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
(a) Basis of presentation
The accompanying anaudited consolidated financial statements ("CFS")
were prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and
have been consistently applied for information pursuant to the rules and regulations of the Securities Exchange Commission (the "SEC").The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities Exchange
Commission (the "SEC"). The accompanying unaudited condensed consolidated financial statements include the financial statements
of the Company and its subsidiaries. All intercompany balances and transactions are eliminated upon consolidation. Accordingly, certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been
omitted pursuant to the afore-mentioned SEC rules and regulations. These unaudited condensed consolidated financial statements should
be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal years ended 2024 and 2023.
Operating results for the six-month period ended December 31, 2024 are not necessarily indicative of the results that may be expected
for the year ending June 30, 2025.
(b) Principles of consolidation
The CFS include the financial statements of the
Company, its subsidiaries for which the Company exercises control and, when applicable, entities in which the Company has a controlling
financial interest or the ultimate primary beneficiary.
All transactions and balances between the Company
and its subsidiaries were eliminated in the consolidation.
(c) Use of estimates
In preparing the CFS in conformity with U.S. GAAP, management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities
at the dates of the CFS, as well as the reported amounts of revenue and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include, but are not limited to, the assessment of the allowance for expected credit loss, useful lives
of property and equipment and intangible assets, ,impairment of long-lived assets, realization of deferred tax assets. Actual results
could differ from those estimates.
(d) Cash and cash equivalents
Cash includes cash on hand and demand deposits
placed with banks or other financial institutions, which are unrestricted as to withdrawal or use in accounts maintained with commercial
banks. The Company maintains bank accounts in mainland China. Cash balances in bank accounts in mainland China are not insured by the
Federal Deposit Insurance Corporation or other programs.
(e) Trade receivable, net
Trade receivables are presented net of allowance for expected credit
loss. The Company reduces trade receivable by recording an allowance for expected credit loss to account for the estimated impact of collection
issues resulting from a client's inability or unwillingness to pay valid obligations to the Company. The Company determines the
adequacy of allowance for expected credit loss based on individual account analysis, historical collection trend, and best estimate of
specific losses on individual exposures. The Company establishes a provision for doubtful receivable when there is objective evidence
that the Company may not be able to collect amounts due. Actual amounts received may differ from management's estimate of credit
worthiness and the economic environment.
(f) Advances to suppliers, net
Advances to suppliers represents balances paid
to suppliers for services that have not been provided or received. The Company reviews its advances to suppliers periodically and makes
general and specific allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
(g) Property and equipment, net
Property and equipment are carried at cost and
are depreciated on the straight-line basis over the estimated useful lives of the underlying assets. The cost of repairs and maintenance
is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated
depreciation and amortization are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.
The Company examines the possibility of decreases in the value of its property and equipment when events or changes in circumstances reflect
the fact that their recorded value may not be recoverable.
Estimated useful lives are as follows, taking
into account the assets' estimated residual value:
Category Estimated useful lives
Electronic equipment 3 years

Frequently Asked Questions

What are the total assets of Haoxi Health Technology Limited?

Total assets as of December 31, 2024, amount to $22,066,772.

What was Haoxi's net income for the six months ended December 31, 2024?

Haoxi reported a net loss of $232,533 for the six months ended December 31, 2024.

How much cash did Haoxi hold at the end of December 2024?

Haoxi had $9,096,424 in cash at the end of December 2024.

What was the gross profit for Haoxi in the last six months?

Haoxi's gross profit for the six months ended December 31, 2024, was $480,393.

What is the shareholders' equity of Haoxi as of December 2024?

As of December 31, 2024, shareholders' equity totaled $18,742,723.

Last updated: Apr 23, 2025